Precision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC trimmed its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 9.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 49,199 shares of the company’s stock after selling 5,000 shares during the period. Moloney Securities Asset Management LLC’s holdings in Precision BioSciences were worth $479,000 at the end of the most recent quarter.

Separately, Janus Henderson Group PLC acquired a new stake in Precision BioSciences in the 1st quarter valued at approximately $7,739,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Price Performance

NASDAQ:DTIL opened at $10.88 on Friday. The firm has a market capitalization of $75.35 million, a PE ratio of -1.46 and a beta of 1.74. The business’s fifty day moving average price is $9.55 and its 200 day moving average price is $11.31. Precision BioSciences, Inc. has a 12 month low of $8.25 and a 12 month high of $19.43.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $3.46 earnings per share for the quarter, topping the consensus estimate of ($0.77) by $4.23. The business had revenue of $49.90 million during the quarter, compared to the consensus estimate of $8.50 million. Precision BioSciences had a net margin of 19.36% and a negative return on equity of 10.76%. During the same quarter in the previous year, the firm earned ($3.00) EPS. As a group, equities analysts anticipate that Precision BioSciences, Inc. will post -2.99 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research note on Thursday, August 22nd.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.